Chennai, July 1 -- The Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) in Puducherry has achieved a significant milestone by becoming the first centre in India to enroll a newborn in the NeoSep1 international clinical trial to advance Neonatal Sepsis treatment.
This multicentre study is coordinated by the Global Antibiotic Research and Development Partnership (GARDP), a not-for-profit organisation dedicated to developing and ensuring equitable access to treatments for drug-resistant infections.
Over the next three years, the trial aims to enrol nearly 3,000 newborns across hospitals in Asia and Africa to evaluate safe, effective, and affordable antibiotic combinations for neonatal sepsis, a PIB release said on...